Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Discovery and characterization of novel subtype-selective allosteric agonists for the investigation of M(1) receptor function in the central nervous system.

Lebois EP, Bridges TM, Lewis LM, Dawson ES, Kane AS, Xiang Z, Jadhav SB, Yin H, Kennedy JP, Meiler J, Niswender CM, Jones CK, Conn PJ, Weaver CD, Lindsley CW.

ACS Chem Neurosci. 2010;1(2):104-121.

2.

Involvement of a subpopulation of neuronal M4 muscarinic acetylcholine receptors in the antipsychotic-like effects of the M1/M4 preferring muscarinic receptor agonist xanomeline.

Dencker D, Wörtwein G, Weikop P, Jeon J, Thomsen M, Sager TN, Mørk A, Woldbye DP, Wess J, Fink-Jensen A.

J Neurosci. 2011 Apr 20;31(16):5905-8. doi: 10.1523/JNEUROSCI.0370-11.2011.

3.

Glutamate signaling in the pathophysiology and therapy of schizophrenia.

Lin CH, Lane HY, Tsai GE.

Pharmacol Biochem Behav. 2012 Feb;100(4):665-77. doi: 10.1016/j.pbb.2011.03.023. Epub 2011 Apr 1. Review.

PMID:
21463651
4.

Discovery and development of a second highly selective M1 Positive Allosteric Modulator (PAM).

Bridges TM, Reid PR, Lewis LM, Dawson ES, Weaver CD, Wood MR, Lindsley CW.

Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-.
2010 Mar 31 [updated 2010 Oct 29].

5.

Discovery and development of the a highly selective M1 Positive Allosteric Modulator (PAM).

Bridges TM, Lewis LM, Dawson ES, Weaver CD, Lindsley CW.

Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-.
2010 Feb 26 [updated 2010 Oct 20].

6.

Discovery of a Highly Selective in vitro and in vivo M4 Positive Allosteric Modulator (PAM).

Lewis LM, Bridges TM, Niswender CM, Weaver CD, Lindsley CW.

Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-.
2009 Sep 1 [updated 2010 Oct 20].

7.

Hemispheric comparisons of neuron density in the planum temporale of schizophrenia and nonpsychiatric brains.

Smiley JF, Rosoklija G, Mancevski B, Pergolizzi D, Figarsky K, Bleiwas C, Duma A, Mann JJ, Javitt DC, Dwork AJ.

Psychiatry Res. 2011 Apr 30;192(1):1-11. doi: 10.1016/j.pscychresns.2010.11.007. Epub 2011 Mar 5.

8.

Preclinical profile of a novel metabotropic glutamate receptor 5 positive allosteric modulator.

Spear N, Gadient RA, Wilkins DE, Do M, Smith JS, Zeller KL, Schroeder P, Zhang M, Arora J, Chhajlani V.

Eur J Pharmacol. 2011 Jun 1;659(2-3):146-54. doi: 10.1016/j.ejphar.2011.02.003. Epub 2011 Feb 16.

PMID:
21335002
9.

Glycine transporter 1 as a potential therapeutic target for schizophrenia-related symptoms: evidence from genetically modified mouse models and pharmacological inhibition.

Möhler H, Boison D, Singer P, Feldon J, Pauly-Evers M, Yee BK.

Biochem Pharmacol. 2011 May 1;81(9):1065-77. doi: 10.1016/j.bcp.2011.02.003. Epub 2011 Feb 17.

PMID:
21333635
10.
11.

Thalamic pathology in schizophrenia.

Cronenwett WJ, Csernansky J.

Curr Top Behav Neurosci. 2010;4:509-28. Review.

PMID:
21312411
12.

Prefrontal cortical circuits in schizophrenia.

Volk DW, Lewis DA.

Curr Top Behav Neurosci. 2010;4:485-508. Review.

PMID:
21312410
13.

Placebo response in clinical trials with schizophrenia patients.

Kinon BJ, Potts AJ, Watson SB.

Curr Opin Psychiatry. 2011 Mar;24(2):107-13. doi: 10.1097/YCO.0b013e32834381b0. Review.

PMID:
21285702
14.

Pharmacogenetic analysis of the mGlu2/3 agonist LY2140023 monohydrate in the treatment of schizophrenia.

Liu W, Downing AC, Munsie LM, Chen P, Reed MR, Ruble CL, Landschulz KT, Kinon BJ, Nisenbaum LK.

Pharmacogenomics J. 2012 Jun;12(3):246-54. doi: 10.1038/tpj.2010.90. Epub 2010 Dec 21.

PMID:
21173788
15.

Discovery of benzoylisoindolines as a novel class of potent, selective and orally active GlyT1 inhibitors.

Pinard E, Alberati D, Bender M, Borroni E, Brom V, Burner S, Fischer H, Hainzl D, Halm R, Hauser N, Jolidon S, Lengyel J, Marty HP, Meyer T, Moreau JL, Mory R, Narquizian R, Norcross RD, Schmid P, Wermuth R, Zimmerli D.

Bioorg Med Chem Lett. 2010 Dec 1;20(23):6960-5. doi: 10.1016/j.bmcl.2010.09.124. Epub 2010 Oct 7.

PMID:
20974532
16.

Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity.

Rodriguez AL, Grier MD, Jones CK, Herman EJ, Kane AS, Smith RL, Williams R, Zhou Y, Marlo JE, Days EL, Blatt TN, Jadhav S, Menon UN, Vinson PN, Rook JM, Stauffer SR, Niswender CM, Lindsley CW, Weaver CD, Conn PJ.

Mol Pharmacol. 2010 Dec;78(6):1105-23. doi: 10.1124/mol.110.067207. Epub 2010 Oct 5.

17.

Glutamatergic theories of schizophrenia.

Javitt DC.

Isr J Psychiatry Relat Sci. 2010;47(1):4-16. Review.

18.

Glycine transporter (GlyT1) inhibitors with reduced residence time increase prepulse inhibition without inducing hyperlocomotion in DBA/2 mice.

Kopec K, Flood DG, Gasior M, McKenna BA, Zuvich E, Schreiber J, Salvino JM, Durkin JT, Ator MA, Marino MJ.

Biochem Pharmacol. 2010 Nov 1;80(9):1407-17. doi: 10.1016/j.bcp.2010.07.004. Epub 2010 Jul 15.

PMID:
20637735
19.

Impact of metabotropic glutamate 2/3 receptor stimulation on activated dopamine release and locomotion.

Pehrson AL, Moghaddam B.

Psychopharmacology (Berl). 2010 Sep;211(4):443-55. doi: 10.1007/s00213-010-1914-8. Epub 2010 Jun 29.

20.

Allosteric activators of muscarinic receptors as novel approaches for treatment of CNS disorders.

Digby GJ, Shirey JK, Conn PJ.

Mol Biosyst. 2010 Aug;6(8):1345-54. doi: 10.1039/c002938f. Epub 2010 Jun 25. Review. Erratum in: Mol Biosyst. 2011 Dec;7(12):3376.

Supplemental Content

Support Center